Snorting Suboxone triggers a different pharmacological response than taking it under the tongue as prescribed. The naloxone component, which is normally inactive when the film or tablet dissolves sublingually, becomes significantly more bioavailable through the nasal membranes. This can cause withdrawal symptoms in opioid-dependent individuals, nasal tissue damage from inactive ingredients, and a complicated mix of effects that are neither a clean high nor effective treatment.
Why Naloxone Activates When Snorted
Suboxone contains two drugs: buprenorphine (a partial opioid) and naloxone (an opioid blocker). The formulation is designed so that when you dissolve it under your tongue, naloxone has poor absorption and essentially does nothing. Buprenorphine absorbs well sublingually and provides its therapeutic effect unimpeded.
Snorting changes the equation. Intranasal administration delivers roughly 24 to 30 percent of the naloxone into the bloodstream, producing plasma concentrations comparable to doses known to precipitate withdrawal in opioid-dependent people. At the same time, buprenorphine’s nasal absorption sits around 38 to 44 percent. So both drugs get absorbed, but naloxone now arrives in amounts large enough to cause real problems.
The naloxone doesn’t just partially block the buprenorphine. Research from a controlled study in physically dependent opioid users found that intranasal Suboxone produced “modest and transient opioid withdrawal-like effects” in the first hour after use, while simultaneously delaying and blunting the agonist effects that buprenorphine normally provides. In other words, you get hit with withdrawal symptoms before any opioid effect kicks in, and when the opioid effect does arrive, it’s weaker than it would be from buprenorphine alone.
What It Actually Feels Like
The experience of snorting Suboxone depends heavily on your current level of opioid dependence and what you’re dependent on. For someone dependent on full opioid agonists like heroin or fentanyl, the naloxone can trigger precipitated withdrawal: sweating, nausea, cramping, anxiety, and agitation that comes on within minutes. This withdrawal phase is typically short-lived but intensely unpleasant.
For people already maintained on buprenorphine (meaning they take Suboxone or Subutex daily as prescribed), the picture looks different. Intranasal buprenorphine/naloxone doesn’t precipitate withdrawal in buprenorphine-maintained individuals. However, the naloxone still dampens the positive subjective effects. In controlled studies, participants reported less “liking,” less “high,” and more aversive effects from the combination compared to buprenorphine alone. The addition of naloxone dose-dependently reduced the rewarding properties while increasing negative sensations.
The onset is also slower than people expect. Unlike heroin, which reaches peak nasal concentrations in about 5 minutes, buprenorphine takes 30 to 45 minutes to reach its maximum plasma levels through the nose. This sluggish onset further limits the rush that someone misusing the drug is typically seeking.
The Ceiling Effect
One counterintuitive finding from clinical research: snorting more Suboxone doesn’t produce a stronger high. In studies comparing 8 mg and 16 mg intranasal doses of buprenorphine, the 16 mg dose produced higher blood levels but was consistently rated lower on positive subjective measures and was less reinforcing than the 8 mg dose. The positive effects appear to plateau and then decline, while the aversive effects increase. This ceiling is built into buprenorphine’s pharmacology as a partial opioid agonist, and snorting doesn’t overcome it.
People already on higher sublingual maintenance doses experienced this even more sharply. As the daily prescribed dose went up, the positive effects of snorting additional buprenorphine trended downward, and the unpleasant effects trended upward. At adequate maintenance doses, there’s very little reinforcing effect left to chase.
Damage to the Nasal Passages
Suboxone tablets and films were never designed to be inhaled through the nose. Both formulations contain a range of inactive ingredients, including starches, polymers, flavoring agents, citric acid, and sugar alcohols like mannitol and maltitol. When crushed and snorted repeatedly, these substances irritate and erode the delicate nasal mucosa.
Citric acid is particularly harsh on nasal tissue, causing chemical burns to the lining of the nasal passages. Insoluble binders like povidone and starch don’t dissolve in nasal secretions. Instead, they accumulate and physically abrade the tissue. Over time, chronic intranasal misuse can lead to persistent nosebleeds, loss of smell, chronic sinus infections, and damage to the nasal septum. The films contain additional ingredients like propylene glycol and a polymer called hypromellose that form a gummy residue not meant to contact nasal tissue.
Impact on Treatment and Addiction Patterns
The faster a drug reaches the brain, the more reinforcing it tends to be. This is why smoking and injecting drugs carry higher addiction potential than swallowing them. Snorting buprenorphine does produce a somewhat faster onset than sublingual dosing, and studies confirm that intranasal buprenorphine alone generates meaningful increases in drug “liking” and “high” compared to placebo. Participants in one study were willing to pay for the experience and self-administered it more than placebo under certain conditions.
But here’s the critical distinction: these reinforcing effects were measured with buprenorphine alone. The naloxone in Suboxone specifically counteracts this pattern. In the same research, naloxone reduced how much participants liked the drug, increased unpleasant effects, and decreased self-administration. The combination was designed to make this route of misuse unrewarding, and the data suggest it partially works.
Still, “partially” matters. Some people with lower levels of physical dependence, or those primarily dependent on buprenorphine itself rather than full agonists, may still find intranasal Suboxone somewhat reinforcing. This is why the FDA label specifically warns clinicians that some opioid-dependent individuals, particularly those with low-level dependence, do misuse buprenorphine/naloxone combinations intranasally. The behavior can undermine treatment by shifting the relationship with the medication from therapeutic to compulsive, eroding the stability that medication-assisted treatment is designed to provide.
Overdose Risk
Buprenorphine’s ceiling effect on breathing makes fatal overdose from the drug alone relatively rare compared to full agonists like heroin or fentanyl. But snorting introduces variables that increase risk. Combining snorted Suboxone with benzodiazepines, alcohol, or other sedatives removes that safety margin. The respiratory depression from these combinations can be fatal even though buprenorphine alone has a ceiling. Unpredictable absorption through damaged nasal tissue also makes dosing less consistent over time, adding another layer of risk that doesn’t exist with supervised sublingual use.